Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology
Wolfgang Brück MD
Department of Neuropathology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorAndreas Bitsch MD
Department of Neurology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorHerbert Kolenda MD
Department of Neurosurgery, University of Göttingen, Göttingen, Germany
Search for more papers by this authorCorresponding Author
Dr. Yvonne Brück MD
Department of Neuropathology, University of Göttingen, Göttingen, Germany
Institut für Neuropathologie, Georg-August-Universität, Robert-Koch-Str 40, 37075 Göttingen, GermanySearch for more papers by this authorMichael Stiefel MD
Department of Neuroradiology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorHans Lassmann MD
Institute of Neurology, University of Vienna, Vienna, Austria
Search for more papers by this authorWolfgang Brück MD
Department of Neuropathology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorAndreas Bitsch MD
Department of Neurology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorHerbert Kolenda MD
Department of Neurosurgery, University of Göttingen, Göttingen, Germany
Search for more papers by this authorCorresponding Author
Dr. Yvonne Brück MD
Department of Neuropathology, University of Göttingen, Göttingen, Germany
Institut für Neuropathologie, Georg-August-Universität, Robert-Koch-Str 40, 37075 Göttingen, GermanySearch for more papers by this authorMichael Stiefel MD
Department of Neuroradiology, University of Göttingen, Göttingen, Germany
Search for more papers by this authorHans Lassmann MD
Institute of Neurology, University of Vienna, Vienna, Austria
Search for more papers by this authorAbstract
Magnetic resonance imaging (MRI) is widely used to evaluate and monitor disease activity in inflammatory demyelinating central nervous system (CNS) diseases such as multiple sclerosis. The present study aimed at correlating MRI findings with histological parameters in 6 cases of biopsy-proven inflammatory demyelination of the CNS. The earliest stages of demyelinating activity manifested as almost isointense lesions with a massive gadolinium-DTPA (Gd-DTPA) enhancement in T1-weighted scans. In T2-weighted scans, early active lesions formed a border of decreased intensity compared with the lesion center and the perifocal edema. The morphological correlate of this pattern in our patients was activated macrophages in the zone of myelin destruction at the plaque border. Late active lesions were hypointense in T1 and hyperintense in T2 scans. Inactive demyelinated and remyelinating lesions were hyperintense in T2 scans and enhanced inhomogenously after Gd-DTPA application. T1 scans revealed major differences in the degree of hypointensity that correlated with the extent of axonal damage, extracellular edema, and the degree of demyelination or remyelination.
References
- 1
Lassmann H.
Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis.
Berlin: Springer-Verlag,
1983
10.1007/978-3-642-45558-2 Google Scholar
- 2 Prineas JW. The neuropathology of multiple sclerosis. In: JC Koetsier ed. Demyelinating Diseases. Amsterdam: Elsevier Science, 1985: 213–257
- 3 Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259–274
- 4 McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992; 18: 319–334
- 5 McDonald WI, Barnes D. Lessons from magnetic resonance imaging in multiple sclerosis. Trends Neurosci 1989; 12: 376–379
- 6 Goodkin DE, Rudick RA, Ross JS. The use of brain magnetic resonance imaging in multiple sclerosis. Arch Neurol 1994; 51: 505–516
- 7 McDonald WI. NMR in diagnosis, monitoring treatment and epidemiology of multiple sclerosis. Acta Neurol Scand 1995; 161: (suppl 161) 52–53
- 8 Poser S, Scheidt P, Kitze B, et al. Impact of magnetic resonance imaging (MRI) on the epidemiology of MS. Acta Neurol Scand 1991; 83: 172–175
- 9 Tas MW, Barkhof F, van Walderveen MAA, et al. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR 1995; 16: 259–264
- 10 Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 34: 683–688
- 11 Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180: 467–474
- 12 Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661–669
- 13 Barnes D, Munro PMG, Youl BD, et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991; 114: 1271–1280
- 14 Estes ML, Rudick RA, Barner GH, et al. Stereotactic biopsy of an active multiple sclerosis lesion. Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Arch Neurol 1990; 47: 1299–1303
- 15 Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65–73
- 16 Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788–796
- 17 Poser S, Lier W, Bruhn H, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992; 86: 579–585
- 18 Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231
- 19 Gunn C, Richards MK, Linington C. The immune response to myelin proteolipid protein in the Lewis rat: identification of the immunodominant B cell epitope. J Neuroimmunol 1990; 27: 155–162
- 20 Piddlesden SJ, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143: 555–564
- 21 Radzun HJ, Hansmann ML, Heidebrecht HJ, et al. Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. Lab Invest 1991; 65: 306–315
- 22 Zwadlo G, Schlegel R, Sorg C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J Immunol 1986; 137: 512–518
- 23 Bhardwaj RS, Zotz C, Zwadlo-Klarwasser G, et al. The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol 1992; 22: 1891–1897
- 24 Zwadlo G, Brocker EB, von Bassewitz DB, et al. A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol 1985; 134: 1487–1492
- 25
Bruck W,
Huitinga I,
Dijkstra CD.
Liposome-mediated monocyte depletion during Wallerian degeneration defines the role of hematogenous phagocytes in myelin removal.
J Neurosci Res
1996;
46: 477–484
10.1002/(SICI)1097-4547(19961115)46:4<477::AID-JNR9>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 26 Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991; 114: 1013–1023
- 27 Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994; 44: 2120–2124
- 28 Mammi S, Filippi M, Martinelli V, et al. Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurol Scand 1996; 94: 93–96
- 29 McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758–766
- 30 Rovaris M, Barnes D, Woodroofe N, et al. Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 1996; 243: 536–542
- 31 Kidd D, Thompson AJ, Kendall BE, et al. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994; 57: 1070–1072
- 32 Rieckmann P, Altenhofen B, Riegel A, et al. Soluble adhesion molecules (sVCAM and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997; 41: 326–333
- 33 Hartung H-P, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995; 38: 186–193
- 34 van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995; 45: 1684–1690
- 35 Powell T, Sussman JG, Davies-Jones GAB. MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals. AJNR 1992; 13: 1544–1546
- 36 Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229–235
- 37 Hawkins CP, Munro PMG, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 365–378
- 38 Seeldrayers PA, Syha J, Morrissey SP, et al. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis. J Neuroimmunol 1993; 46: 199–206
- 39 Namer IJ, Steibel J, Piddlesden SJ, et al. Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis. J Neuroimmunol 1994; 54: 41–50
- 40 Morrissey SP, Stodal H, Zettl U, et al. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996; 119: 239–248
- 41 Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989; 60: 714–725
- 42 Truyen L, van Waesberghe JHTM, van Walderveen MAA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469–1476
- 43 Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583–1592
- 44 Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41: 385–391
- 45 Stewart WA, Alvord ECJr, Hruby S, et al. Magnetic resonance imaging of experimental allergic encephalomyelitis in primates. Brain 1991; 114: 1069–1096
- 46 Teresi LM, Hovda D, Seeley AB, et al. MR imaging of experimental demyelination. AJR Am J Roentgenol 1989; 152: 1291–1298
- 47 Loevner LA, Grossman RI, McGowan JC, et al. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. AJNR 1995; 16: 1473–1479
- 48 Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49–58
- 49 McDonald WI. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 1994; 53: 338–343
- 50 Koopmans RA, Li DKB, Oger JJF, et al. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 1989; 39: 959–963
- 51 Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53: 625–636
- 52 Claudio L, Raine CS, Brosnan CF. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol (Berl) 1995; 90: 228–238
- 53 Mehta RC, Pike B, Enzmann DR. Measure of magnetization transfer in multiple sclerosis demylinating plaques, white matter ischemic lesions, and edema. AJNR 1996; 17: 1051–1055
- 54 Petrella JR, Grossman RI, McGowan JC, et al. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR 1996; 17: 1041–1049
- 55 Arnold DL, Matthews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31: 235–241
- 56 De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901–909